Developing RNA vaccines to protect against hantaviruses
Nucleic acid vaccines targeting hantaviruses
This study is working on new RNA vaccines to help protect people from hantaviruses, which can cause serious illnesses, by testing how well these vaccines work in animals to prepare for any future outbreaks.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-10863661 on NIH RePORTER |
What this research studies
This research focuses on creating innovative RNA vaccines to combat hantaviruses, which are known to cause severe diseases in humans. The project aims to convert existing DNA vaccines into lipid nanoparticle mRNA vaccines and test their effectiveness in animal models. By investigating how these vaccines induce immune responses, the research seeks to provide a rapid response to potential outbreaks of hantavirus infections. The study will specifically target viruses like the Andes virus, Sin Nombre virus, and Hantaan virus.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at risk of hantavirus exposure, particularly those in endemic regions.
Not a fit: Patients who are not at risk of hantavirus infections or those with existing immunity to these viruses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective vaccines that protect against dangerous hantavirus infections, potentially saving lives during outbreaks.
How similar studies have performed: Other research has shown promise in developing RNA vaccines for various viral infections, indicating a potential for success in this novel approach.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Bukreyev, Alexander — Vanderbilt University Medical Center
- Study coordinator: Bukreyev, Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.